---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-098535"
form_type: "8-K"
ticker: "AKTX"
cik: "0001541157"
company_name: "Akari Therapeutics Plc"
filed_at: "2024-08-19T23:59:59+00:00"
generated_at: "2026-05-31T08:40:09.812672+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Akari appoints Samir Patel as interim CEO; merger with Peak Bio on track for Q4 2024

## Summary
- Samir R. Patel appointed interim CEO with employment contract consisting solely of equity compensation.
- Merger with Peak Bio remains on track for Q4 2024 closing; combined entity to focus on ADC platform and PAS-nomacopan for GA.
- Raised $7.6M in private placement and issued $1M in convertible notes to CEO and Chairman for operating capital.
- Reported net loss of $7.6M for Q2 2024 vs $4.0M in Q2 2023; cash at $4.2M at June 30, 2024.
- Received positive pre-IND feedback from FDA for PAS-nomacopan in geographic atrophy; IND filing planned for H2 2025.

## SEC filing metadata
- accession: 0000950170-24-098535
- form_type: 8-K
- ticker: AKTX
- cik: 0001541157
- company_name: Akari Therapeutics Plc
- filed_at: 2024-08-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1541157/000095017024098535/0000950170-24-098535-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1541157/000095017024098535/aktx-20240819.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-098535
- JSON: https://secwatch.observer/filing/0000950170-24-098535.json
- Plain text: https://secwatch.observer/filing/0000950170-24-098535.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.